loader image
Saturday, May 18, 2024
79.9 F
McAllen
We Welcome your Press Release
- Advertisement -

AG Paxton Sues Drug Manufacturer Tris Pharma, for Defrauding Texas Taxpayers 

Translate to Spanish or other 102 languages!

The Office of the Attorney General’s Civil Medicaid Fraud Division has sued Tris Pharma, Inc. and Tris CEO Ketan Mehta for defrauding the Texas Medicaid program by making false statements in violation of the Texas Medicaid Fraud Prevention Act, now known as the Texas Health Care Program Fraud Prevention Act (“THFPA”). Image for illustration purposes
The Office of the Attorney General’s Civil Medicaid Fraud Division has sued Tris Pharma, Inc. and Tris CEO Ketan Mehta for defrauding the Texas Medicaid program by making false statements in violation of the Texas Medicaid Fraud Prevention Act, now known as the Texas Health Care Program Fraud Prevention Act (“THFPA”). Image for illustration purposes
- Advertisement -

AUSTIN, Texas – The Office of the Attorney General’s Civil Medicaid Fraud Division has sued Tris Pharma, Inc. and Tris CEO Ketan Mehta for defrauding the Texas Medicaid program by making false statements in violation of the Texas Medicaid Fraud Prevention Act, now known as the Texas Health Care Program Fraud Prevention Act (“THFPA”).   

Tris manufactured a potent attention-deficit/hyperactivity disorder (“ADHD”) drug for children called Dyanavel XR and targeted Texas Medicaid with a fraudulent marketing scheme for the purpose of receiving taxpayer reimbursements through the program. In 2015, Tris launched Dyanavel into a saturated ADHD medication market and sought to differentiate the drug from competitors. To do so, Mehta and Tris pushed false claims that overstated Dyanavel’s efficacy.   

Tris directed their sales representatives to deliver false and misleading messages about Dyanavel to doctors in Texas, including Medicaid doctors. Sales representatives falsely told doctors that Dyanavel worked significantly faster than other drugs and provided other unproven benefits to pediatric patients. 

- Advertisement -

The filing explains that Tris’s “false and/or misleading messages regarding the efficacy of Dyanavel XR were disseminated repeatedly on thousands of sales calls to Texas Medicaid providers and decision makers.”    

“The lengths to which this company and their leadership went to defraud our state and the patients taking this medication are shocking,” said Attorney General Paxton. “Pharmaceutical companies who violate the public’s trust and hurt the people of Texas will be brought to justice to the fullest extent of the law.”   

The lawsuit was initially filed under seal, but the judge has since unsealed the petition at the Attorney General’s request. To read the unsealed petition, click here

- Advertisement -
- Advertisement -

- Advertisement -

More Articles

New Imaging Software Improves Lung Diagnosis For 30% Of Patients Who Can’t Tolerate Contrast Dye

As a result, the software program helps doctors and researchers get consistent patient data, leading to better diagnoses and specifics on where to target potential therapies - all without contrast dye.

Moms Club Event Focused on Maternal Mental Health 

A study found that maternal mental health conditions such as depression and anxiety disorders affected 13.2% of Texas mothers.

Final Nursing Home Staffing Rule Would Require 102,000 Additional Caregivers, Cost $6.5B Per Year

The AHCA/NCAL analysis of the final rule uses staffing, cost, and facility data from the federal government: CMS' Payroll Based Journal, Medicare Cost Reports, and Care Compare. 

Community Health Fair to Offer Vital Health Services in Pharr, May 18th

This initiative reflects Operation Christmas RGV's ongoing commitment to enhancing the health and well-being of residents in the Pharr area
- Advertisement -
×